Brachial plexus neuritis

Summary

Brachial plexus neuritis (MONDO:0006682) is a disease and 2 clinical trials. A subtype of neuritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	brachial plexus neuritis
Mondo ID	MONDO:0006682
EFO	EFO:1000843
MeSH	D020968
DOID	DOID:3689
NCIT	C84600
SNOMED CT	72893007
UMLS	C0221759
MedGen	113170
GARD	0024458
MedDRA	10073002
Anatomy (UBERON)	UBERON:0001814
Is cancer (heuristic)	no

Also known as: acute brachial neuritis · acute brachial neuritis syndrome · acute brachial radiculitis syndrome · acute shoulder neuritis · brachial nerve plexus neuritis · idiopathic neuralgic amyotrophy · neuritis of brachial nerve plexus · parsonage Turner syndrome

Disease family

This is a subtype of neuritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › neuritis › brachial plexus neuritis

Related subtypes (6): neuroretinitis, mononeuritis simplex, neuritis of upper limb, motor nerve neuritis, vestibular neuronitis, polyneuritis

Subtypes (1): radial nerve lesion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ibuprofen.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06740656	Not specified	NOT_YET_RECRUITING	Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature
NCT03441347	Not specified	COMPLETED	Neuralgic Amyotrophy: Central Reorganization and Rehabilitation After Peripheral Dysfunction